PDF(Pubmed)
Abstract：
The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic potential in microvascular ischaemic complications associated with peripheral artery disease, with subsequent analysis showing reduction in the incidence of lower extremity ischaemic ulceration or gangrene. Reassurance about the safety of pemafibrate, together with emerging data from PROMINENT and experimental studies, also suggest benefit with pemafibrate in non-alcoholic fatty liver disease (alternatively referred to as metabolic dysfunction-associated steatotic liver disease) and microangiopathy associated with diabetes, which merit further study.
摘要：
PROMINENT试验的中性结果引发了对pemafrabate未来的质疑。本评论讨论了审判中缺乏益处的可能原因。有,然而,提示与外周动脉疾病相关的微血管缺血性并发症的治疗潜力的指标，随后的分析显示下肢缺血性溃疡或坏疽的发生率降低。关于培美贝的安全性的保证，结合来自PROMINENT和实验研究的新数据，还建议在非酒精性脂肪性肝病（或称为代谢功能障碍相关的脂肪变性肝病）和与糖尿病相关的微血管病中使用培美贝贝特的益处。这值得进一步研究。
